⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512605 | 0.88 | — | — | |
| SCHEMBL4512756 | 0.88 | — | — | |
| SCHEMBL4512007 | 0.68 | — | — | |
| SCHEMBL5722147 | 0.66 | — | — | |
| SCHEMBL4499393 | 0.60 | — | — | |
| SCHEMBL4495883 | 0.59 | — | — | |
| SCHEMBL4510411 | 0.59 | — | — | |
| SCHEMBL3241529 | 0.58 | — | — | |
| SCHEMBL29816457 | 0.57 | IDO1 (0.31) | — | |
| SCHEMBL1120338 | 0.57 | IDO1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |